Cardiovascular Outcomes Associated With Hypoplastic Left Heart Syndrome Versus Other Types of Single Right Ventricle: A Multicenter Study Authors: Nabil Dib, Nancy Poirier, Michelle Samuel, Sewanou Hermann Honfo, Ali Zaidi, Alexander R. Opotowsky, François‐Pierre Mongeon, Blandine Mondésert, Joseph Kay, Reda Ibrahim, Robert M. Hamilton, Anne Fournier, Susan M. Jameson, Annie Dore, Stephen Cook, Scott Cohen, Marie‐A. Chaix, Craig S. Broberg, Jamil Aboulhosn, Paul Khairy Published: 2024 ABSTRACT BackgroundThe univentricular heart with a predominant right ventricle morphology (uRV) has been associated with a higher rate of adverse cardiovascular events. It remains to be determined whether the specific type of uRV influences outcomes.Methods and ResultsA North American multicenter retrospective cohort study was conducted by the Alliance for Adult Research in Congenital Cardiology on individuals with a uRV and total cavopulmonary connection Fontan. The incidence of a composite outcome consisting of all‐cause mortality, cardiac transplantation, atrial arrhythmias, or thromboembolic events was compared among patients with Fontan palliation who had hypoplastic left heart syndrome (HLHS) versus other forms of uRV (non‐HLHS). All components of the composite outcome were classified by a blinded adjudicating committee. Competing risks were taken into account in time‐to‐event analyses. A total of 171 patients with uRV of whom 76 (44.4%) had HLHS were followed for 10.2±5.7 years. The composite outcome occurred in 7.1 versus 2.1 cases per 100 person‐years in patients with HLHS versus non‐HLHS (P<0.0001). In multivariable analyses, HLHS was associated with a significantly higher risk of the composite outcome (hazard ratio [HR], 6.13 [95% CI, 2.92–12.69], P<0.001). Moreover, HLHS was associated with significantly higher rates of all components of the primary outcome.ConclusionsAmong patients with a uRV and Fontan palliation, HLHS is associated with a significantly higher rate of adverse cardiovascular events. Nonstandard Abbreviations and Acronyms hypoplastic left heart syndrome The AntiCoagulation Therapy In Congenital Heart Disease study univentricular heart with predominant right ventricular morphology Clinical PerspectiveWhat Is New? Although it has previously been shown that patients with a predominant right versus left univentricular heart are at higher risk of adverse cardiovascular events, this North American multicenter study found that among the subgroup with univentricular heart with predominant right ventricular morphology, hypoplastic left heart syndrome is associated with significantly greater risk.As the population of survivors with hypoplastic left heart syndrome grows, knowledge of the heightened risks of atrial arrhythmias, thromboembolic complications, and cardiac transplantation or death should be factored into appropriate resource allocation planning. What Are the Clinical Implications? Future studies are required to determine whether the risk for adverse cardiovascular events in patients with hypoplastic left heart syndrome could be mitigated by heightened surveillance and preemptive management approaches. Clinical Perspective What Is New? Although it has previously been shown that patients with a predominant right versus left univentricular heart are at higher risk of adverse cardiovascular events, this North American multicenter study found that among the subgroup with univentricular heart with predominant right ventricular morphology, hypoplastic left heart syndrome is associated with significantly greater risk.As the population of survivors with hypoplastic left heart syndrome grows, knowledge of the heightened risks of atrial arrhythmias, thromboembolic complications, and cardiac transplantation or death should be factored into appropriate resource allocation planning. Although it has previously been shown that patients with a predominant right versus left univentricular heart are at higher risk of adverse cardiovascular events, this North American multicenter study found that among the subgroup with univentricular heart with predominant right ventricular morphology, hypoplastic left heart syndrome is associated with significantly greater risk. Although it has previously been shown that patients with a predominant right versus left univentricular heart are at higher risk of adverse cardiovascular events, this North American multicenter study found that among the subgroup with univentricular heart with predominant right ventricular morphology, hypoplastic left heart syndrome is associated with significantly greater risk. As the population of survivors with hypoplastic left heart syndrome grows, knowledge of the heightened risks of atrial arrhythmias, thromboembolic complications, and cardiac transplantation or death should be factored into appropriate resource allocation planning. As the population of survivors with hypoplastic left heart syndrome grows, knowledge of the heightened risks of atrial arrhythmias, thromboembolic complications, and cardiac transplantation or death should be factored into appropriate resource allocation planning. What Are the Clinical Implications? Future studies are required to determine whether the risk for adverse cardiovascular events in patients with hypoplastic left heart syndrome could be mitigated by heightened surveillance and preemptive management approaches. Future studies are required to determine whether the risk for adverse cardiovascular events in patients with hypoplastic left heart syndrome could be mitigated by heightened surveillance and preemptive management approaches. Future studies are required to determine whether the risk for adverse cardiovascular events in patients with hypoplastic left heart syndrome could be mitigated by heightened surveillance and preemptive management approaches. The common pathway for individuals with single ventricle heart disease is to undergo Fontan palliation, which involves diverting systemic venous return into the pulmonary arteries, thereby bypassing the functionally ineffective pulmonary ventricle. 1 Prior studies in patients with Fontan palliation have documented a higher incidence of adverse cardiovascular events when the univentricular heart is of right (uRV) compared with left ventricular morphology. 2 Hypoplastic left heart syndrome (HLHS), the most common form of uRV, constitutes 25% to 40% of neonatal fatalities and stands as the primary cause of cardiac mortality among neonates. 3 , 4 Although postoperative mortality was exceptionally high in the early years of palliation of HLHS, 5 more recent estimates indicate that around 70% reach adulthood. 6 Despite reductions in operative and long‐term mortality, 7 considerable morbidity persists. 8 , 9 It remains uncertain whether the prognosis is uniform among patients with uRV or whether it differs in the subgroup of patients with HLHS. Therefore, we conducted a multicenter North American study in patients with Fontan palliation to compare the incidence of a composite outcome consisting of new‐onset atrial arrhythmia, thromboembolic event, cardiac transplantation, or death between individuals with HLHS versus other forms of uRV. METHODS Study Design and Patient Population Detailed information regarding the TACTIC (The AntiCoagulation Therapy In Congenital Heart Disease) study has been previously published. 10 , 11 In summary, TACTIC is a multicenter retrospective cohort study conducted in North America, involving 3 Canadian and 9 US centers. The study included patients born in July 2011 or earlier with heterogeneous forms of congenital heart disease followed until December 2013. 11 , 12 For this substudy, only patients with uRV who survived total cavopulmonary connection Fontan completion and were followed at the same institution performing the procedure were included. The data that support the findings of this study are available from the corresponding author upon reasonable request. Data Collection Eligible participants were retrospectively identified from hospital medical and surgical records at each of the 12 participating institutions, with the time of entry into the study defined by the date of Fontan completion. Baseline characteristics, including age, sex, comorbidities, single ventricle morphology, and prior surgical or catheter‐based interventions, were captured at the time of Fontan completion. The presence of ongoing heart failure, pulmonary hypertension, and other comorbidities was also documented. Preoperative heart failure was defined as chronic diuretic use or as New York Heart Association functional class III or IV symptoms, independently of medical therapy. Diagnosis of pulmonary arterial hypertension was made per clinical guidelines available at the time of enrollment. 13 Outcomes of Interest The primary end point comprised a composite of sustained atrial arrhythmia, thromboembolic event, cardiac transplantation, or all‐cause death. Atrial tachyarrhythmia was defined using 12‐lead electrocardiograms or rhythm strips as a sudden‐onset atrial rhythm with a constant rate ≥100 beats/min. 14 Atrial fibrillation was characterized by the absence of recognizable P waves and an irregular ventricular response when atrioventricular conduction was intact. 15 Other atrial arrhythmias were categorized as focal atrial tachycardia if well‐formed P waves were distinguishable electrocardiographically and separated by an isoelectric interval, or if an electrophysiology study demonstrated a circumscribed origin of activation with centrifugal spread. Otherwise, atrial tachycardia was classified as intra‐atrial reentrant tachycardia, a term encompassing all forms of typical and atypical atrial flutter. 14 Thromboembolic complications incorporated both systemic and venous events. Systemic thromboemboli were classified as cardiac, neurologic, peripheral arterial, renal, or mesenteric. 11 Systemic cardiac thromboembolic events were defined as clots within coronary arteries or systemic cardiac chambers. Neurologic events included transient ischemic attacks or strokes, with the former defined as a sudden focal neurologic deficit lasting <24 hours with no accompanying imaging defect. Strokes included deficits persevering for at least 24 hours with or without confirmatory imaging, or deficits persisting <24 hours with positive imaging signs. 16 Peripheral arterial complications were diagnosed based on the 6 cardinal signs of acute limb ischemia: pain, pallor, paralysis, pulse deficit, paresthesia, and poikilothermia. 17 Renal and mesenteric complications necessitated appropriate image confirmation. Venous thromboemboli were further subdivided into cardiac, peripheral venous, and pulmonary events. 11 Venous cardiac events were defined as thrombi within Fontan pathways. These complications were confirmed using echocardiography, magnetic resonance imaging, or angiography, as appropriate. Adjudication Process Adjudication of all components of the primary outcome was performed by a blinded committee of 4 physicians. Inconsistencies were carefully reviewed against case report forms and all other supportive documents and were subjected to discussion for final adjudication. The Montreal Health Innovations Coordinating Center supervised data collection, data integration, and data entry and carried out regular quality assurance checks. The observed error rate of 0.02% before the database lock was below the acceptable limit defined a priori at <0.5%. The study was approved by each participating center's institutional review board, with a waiver of informed consent due to the retrospective nature of the study on deidentified patient data. The study adhered to the principles outlined by the International Council of Harmonization Tripartite Guidelines for Good Clinical Practice and Strengthening the Reporting of Observational Studies in Epidemiology guidelines. 18 Statistical Analysis Continuous variables were expressed as median and interquartile range or mean±SD, as appropriate. Categorical variables were presented as frequencies and percentages. Baseline characteristics of the 2 groups of patients with uRVs (ie, HLHS versus non‐HLHS) were compared using analyses of variance or Wilcoxon rank‐sum tests. Comparisons of categorical variables were performed using chi‐square or Fisher's exact tests, as appropriate. Cox regression models were used to assess the risk of outcomes. Owing to the small number of events, a limited number of potential covariates selected on the basis of substantive knowledge and statistical associations (P values <0.2 in univariable analyses) were considered in multivariable models. Cumulative incidence function curves that accounted for competing risks of death were generated and compared using log‐rank tests. Analyses were performed using Stata software 17.0 (StataCorp, College Station, TX). RESULTS Baseline Characteristics A total of 171 patients with uRV underwent total cavopulmonary connection Fontan completion between 1988 and 2012, 76 (44.4%) of whom had HLHS and 95 (55.6%) other forms of uRV. All but 3 (98.2%) patients received antithrombotic agents, with no difference in rates of antiplatelet or anticoagulation therapy between groups (P=0.99). Among those without HLHS, underlying diagnoses were double outlet right ventricle/mitral valve atresia in 61, unbalanced atrioventricular septal defect in 9, and other forms of uRV in 25 patients. Baseline characteristics are summarized in Table 1. Patients with HLHS had Fontan procedures at a younger age and after a greater number of prior surgeries, particularly Norwood staging and superior cavopulmonary connections. Moreover, patients with HLHS had a lower oxygen saturation and a higher prevalence of fenestrations at the time of Fontan palliation. Other preoperative comorbidities, types of Fontan performed, and presence of a fenestration at last follow‐up were comparable between groups. Time trends for Fontan surgery in patients with HLHS versus non‐HLHS are shown in Figure 1. Table 1Baseline Characteristics of Patients According to Diagnosis at Fontan CompletionAll N=171HLHS N=76Non‐HLHS N=95 P valueClinical characteristicsFemale sex, N (%)73 (42.7)27 (35.5)46 (48.4)0.120Age at Fontan, y3.0 (2.1–4.6)2.4 (1.6–3.3)3.8 (2.5–7.3)<0.001Oxygen saturation post Fontan, %87.3±8.784.2±10.189.5±6.90.005Surgical historyNumber of prior surgeries, N3.2±1.03.5±0.93.0±1.0<0.001Number of prior catheterizations, N1.8±1.42.3±1.31.4±1.3<0.001Blalock‐Thomas‐Taussig shunt, N (%)61 (35.7)25 (32.9)36 (37.9)0.524Waterston shunt, N (%)4 (2.3)0 (0.0)4 (4.2)0.130Norwood procedure, N (%)85 (49.7)65 (85.5)20 (21.1)<0.001Pulmonary artery banding, N (%)15 (8.8)4 (5.3)11 (11.6)0.180Superior cavopulmonary anastomosis, N (%)148 (88.6)73 (96.1)75 (79.0)0.001Bidirectional Glenn shunt, N (%)130 (76.0)62 (81.6)68 (71.6)0.151Hemi‐Fontan, N (%)21 (12.3)13 (17.1)8 (8.4)0.103No prior staging procedure, N (%)9 (5.3)0 (0.0)9 (9.5)0.005Surgical Fontan fenestration, N (%)131 (76.6)70 (92.1)61 (64.2)<0.001Patent fenestration at last follow‐up, N (%)28 (16.4)13 (17.1)15 (15.8)0.838Fontan typeLateral tunnel, N (%)97 (56.7)43 (56.6)54 (56.8)1.000Extracardiac conduit, N (%)74 (43.3)33 (43.4)41 (43.2)1.000Preoperative comorbiditiesCongestive heart failure, N (%)3 (1.8)3 (4.0)0 (0.0)0.086Chronic lung disease, N (%)1 (0.6)0 (0.0)1 (1.1)1.000Thyroid disorder, N (%)1 (0.6)0 (0.0)1 (1.1)1.000HLHS indicates hypoplastic left heart syndrome. Baseline Characteristics of Patients According to Diagnosis at Fontan Completion HLHS indicates hypoplastic left heart syndrome. Time trends for Fontan surgery in patients with HLHS and other forms of single right ventricle (non‐HLHS). HLHS indicates hypoplastic left heart syndrome. Composite Outcomes The mean follow‐up duration was 10.2±5.7 years, with a significantly longer follow‐up observed in patients without HLHS (P<0.001). Adjudicated major cardiovascular adverse outcomes are delineated in Table 2. The incidence of the composite end point, encompassing atrial arrhythmia, thromboembolic events, cardiac transplantation, or mortality, was significantly higher in patients with HLHS versus non‐HLHS, with rates of 7.1 and 2.1 cases per 100 person‐years, respectively (P<0.001). As depicted in Figure 2, the cumulative incidence of the composite outcome 10 and 15 years post‐Fontan surgery was 47.4% and 59.1% in patients with HLHS versus 17.5% and 28.9% in non‐HLHS, respectively (P<0.001). In multivariable analysis, HLHS was independently associated with the composite outcome (hazard ratio [HR], 6.13 [95% CI, 3.08–12.22], P<0.001). Other factors associated with the composite outcome in both univariable and multivariable analyses are listed in Table 3. Table 2Adjudicated Adverse Cardiovascular EventsAll N=171HLHS N=76Non‐HLHS N=95 P valueDeath or cardiac transplantation, N (%)13 (7.6)10 (13.2)3 (3.2)0.014Death, N (%)7 (4.1)6 (7.9)1 (1.1)<0.001Transplantation, N (%)6 (3.5)4 (5.3)2 (2.1)0.202Atrial arrhythmias, N (%)25 (14.6)14 (18.4)11 (11.6)0.031Atrial fibrillation, N (%)5 (2.9)2 (2.6)3 (3.2)Focal atrial tachycardia, N (%)6 (3.5)3 (4.0)3 (3.2)Intra‐atrial reentrant tachycardia, N (%)14 (8.2)9 (11.8)5 (5.3)Thromboembolic events, N (%)18 (10.5)12 (15.8)6 (6.3)0.017Systemic, N (%)12 (7.0)7 (9.2)5 (5.3)Neurologic, N (%)4 (2.3)3 (4.0)1 (1.1)Cardiac systemic circulation, N (%)4 (2.3)2 (2.6)2 (2.2)Renal, N (%)2 (1.2)1 (1.3)1 (1.1)Peripheral, N (%)2 (1.2)1 (1.3)1 (1.1)Fontan pathway/pulmonary arterial, N (%)6 (3.5)5 (6.6)1 (1.1)Fontan pathway, N (%)5 (2.9)4 (5.3)1 (1.1)Pulmonary arterial circulation, N (%)1 (0.6)1 (1.3)0 (0.0)Follow‐up duration, y10.2±5.78.6±4.511.6±6.2<0.001Age at first cardiovascular event, y* 7.4 (3.4, 15.6)4.8 (2.1, 8.9)18.0 (7.0, 22.6)0.037HLHS indicates hypoplastic left heart syndrome.*Median (interquartile range). Adjudicated Adverse Cardiovascular Events HLHS indicates hypoplastic left heart syndrome. Median (interquartile range). Freedom from atrial arrhythmia, thromboembolic event, transplantation, or death according to initial diagnosis at Fontan completion. HLHS indicates hypoplastic left heart syndrome. Table 3Factors Associated With the Primary Outcome (Atrial Arrhythmias, Thromboembolic Events, Cardiac Transplantation, or Death) in Univariable and Multivariable Cox Regression AnalysesVariableUnivariable analysesMultivariable analysis P valueHR (95% CI)Adjusted HR (95% CI)Hypoplastic left heart syndrome3.24 (1.84–5.69)6.13 (3.08–12.22)<0.001Female sex1.01 (0.58–1.76)Age at Fontan, y1.11 (1.04–1.18)1.10 (1.05–1.16)<0.001Surgical era (21st versus 20th century)0.73 (0.65–0.82)Surgical Fontan fenestration0.59 (0.29–1.21)Number of prior surgeries0.96 (0.72–1.29)Number of prior catheterizations0.99 (0.80–1.23)Blalock‐Thomas‐Taussig shunt0.81 (0.46–1.43)Superior cavopulmonary anastomosis0.44 (0.24–0.81)Bidirectional Glenn shunt0.44 (0.26–0.75)0.45 (0.26–0.77)0.003Norwood procedure0.91 (0.48–1.72)Lateral tunnel versus extracardiac Fontan1.07 (0.53–1.64)Pulmonary artery banding1.08 (0.42–2.81)HR indicates hazard ratio. Factors Associated With the Primary Outcome (Atrial Arrhythmias, Thromboembolic Events, Cardiac Transplantation, or Death) in Univariable and Multivariable Cox Regression Analyses HR indicates hazard ratio. Cardiac Transplantation or Death Over the study period, there were 7 deaths, which occurred more frequently in patients with HLHS (6 of 76 [7.9%] versus 1 of 95 [1.1%], P<0.001) and were primarily attributable to cardiovascular causes. In addition, 6 patients underwent cardiac transplantation, 4 of whom had HLHS. Cumulative rates of cardiac transplantation or death 10 and 15 years after Fontan surgery were 7.4% and 11.7%, respectively, corresponding to an overall incidence of 0.8 cases per 100 person‐years. The incidence rate was significantly higher in patients with HLHS versus non‐HLHS (Figure 2): 1.5 versus 0.3 cases per 100 person‐years (HR, 6.84 [95% CI, 1.79–26.15]; P=0.005). The number of prior catheterization procedures was also significantly associated with cardiac transplantation or death in univariable analyses (HR, 1.98 [95% CI, 1.35–2.91], P<0.001). Given the limited number of events, multivariable analysis was not performed for this outcome. Atrial Arrhythmias As illustrated in Figure 3, the cumulative incidence of new‐onset atrial arrhythmia demonstrated a consistent upward trajectory within the 2 Fontan subgroups. Notably, the incidence of atrial arrhythmias was significantly higher in those with HLHS versus non‐HLHS (2.6 versus 1.1 per 100 person‐years, respectively; P<0.001). As detailed in Table 2, a total of 25 cases (14.6%) of atrial arrhythmia were documented, with intra‐atrial reentrant tachycardia accounting for 56%, focal atrial tachycardia for 24%, and atrial fibrillation for 20%. Multivariable analysis, presented in Table 4, revealed an independent association between HLHS and a heightened risk of atrial arrhythmias (HR, 4.28 [95% CI, 1.60–11.57], P=0.004). Additional factors linked to the onset of new atrial arrhythmias are delineated in Table 4. Cumulative incidence of (A) cardiac transplantation or death, (B) atrial arrhythmia, and (C) thromboembolic events according to the diagnosis of HLHS versus non‐HLHS. HLHS indicates hypoplastic left heart syndrome. Table 4Factors Associated With Atrial Arrhythmias and Thromboembolic Events in Multivariable Cox Regression AnalysesAdjusted HR (95% CI) P valueAtrial arrhythmiasHypoplastic left heart syndrome4.28 (1.60–11.57)0.004Age at Fontan, y1.08 (1.00–1.18)0.051Number of prior catheterizations0.71 (0.51–0.98)0.040Thromboembolic eventsHypoplastic left heart syndrome7.59 (1.36–42.52)0.021Oxygen saturation post‐Fontan (%)1.10 (1.00–1.22)0.060HR indicates hazard ratio. Factors Associated With Atrial Arrhythmias and Thromboembolic Events in Multivariable Cox Regression Analyses HR indicates hazard ratio. Thromboembolic Complications As shown in Table 2, a total of 18 thromboembolic events occurred during follow‐up, with 12 systemic and 6 venous events. The resulting cumulative rates 10 and 15 years post‐Fontan surgery were 14.5% and 20.9%, respectively, corresponding to an overall incidence of 1.1 per 100 person‐years (Figure 3). Notably, the rates significantly diverged among patients with HLHS versus non‐HLHS, registering at 2.1 and 0.6 per 100 person‐years, respectively (P<0.001). Thromboembolic events occurred at a median age of 8.5 (interquartile range, 3.1, 28.3) years in patients with HLHS versus 28.3 (interquartile range, 20.0, 31.6) years in those without HLHS (P=0.079). In multivariable analysis, outlined in Table 4, HLHS remained independently associated with the occurrence of thromboembolic events (HR, 7.59 [95% CI, 1.36–42.52], P=0.021). Atrial arrhythmias were not significantly associated with thromboembolic events (P=0.55). DISCUSSION HLHS consists of a spectrum of underdevelopment of the left side of the heart, from the mitral valve to the left ventricular cavity, left ventricular outflow tract, aortic valve, ascending aorta, and aortic arch. It requires a staged cardiac surgical approach for survival. 3 , 4 This North American multicenter study assessed whether the clinical trajectories differed in Fontan patients with HLHS compared with other forms of uRV. The study revealed that HLHS was associated with a substantially higher risk of adverse cardiovascular events, such as atrial arrhythmia, thromboembolic complication, cardiac transplantation, or death. Cardiac Transplantation and Death Consistent with the magnitude of effect observed for the primary composite outcome, HLHS was associated with a similar increase in the risk of cardiac transplantation or death when compared with other forms of uRV. These observations have implications with regard to the projected needs of patients with Fontan palliation and underscore the growing challenges that could be anticipated over the next 2 decades as the first cohort of survivors with HLHS ages. 19 For example, the observed high rate of cardiac transplantation or death could potentially affect transplant accessibility, which is already a critical issue. In the context of limited effectiveness and availability of conventional therapies, addressing this problem requires dedicated efforts to explore novel advanced treatment avenues for Fontan circulatory failure. 20 Atrial Arrhythmia Although the surgical transition from an atriopulmonary to a total cavopulmonary connection Fontan has mitigated the incidence of atrial arrhythmia, 10 this complication persists as a major morbidity in patients with lateral tunnels and extracardiac conduits. 21 In this multicenter cohort of patients with uRV, all of whom had a total cavopulmonary connection Fontan, approximately 25% experienced an atrial arrhythmia by 15 years of follow‐up. Reasons as to why HLHS is associated with an increase in the incidence of atrial arrhythmias when compared with other forms of uRV remain speculative. The heightened arrhythmic risk associated with HLHS may reflect the greater number of prior surgeries and particularities of the interventions performed. For example, the Pediatric Heart Network assessed the development of arrhythmias after a Norwood procedure in 544 patients and found that arrhythmias were associated with a longer ventilation time and length of stay. 22 Removal of the atrial septum primum to create an unrestrictive intra‐atrial communication has also been associated with rhythm abnormalities. 23 In addition, a recent study showed that impaired myocardial perfusion in patients with HLHS 24 may contribute to early systolic and diastolic ventricular failure. 25 Impaired myocardial perfusion requires further investigation but may be an important contributor to earlier ventricular failure in patients with HLHS compared with other forms of uRV, which in turn can affect adverse arrhythmogenic remodeling changes. 21 , 26 Thromboembolic Events The thromboembolic event rate, another important concern in patients with uRV and Fontan palliation, was likewise significantly higher in those with HLHS versus non‐HLHS. Further studies are required to elucidate the underlying reasons. The lack of a significant association observed between atrial arrhythmias and thromboembolic events may reflect insufficient statistical power or mitigating effects of therapy (eg, anticoagulation). It remains possible that the increased incidence of atrial arrhythmias and heart failure in patients with HLHS, with resulting structural chamber dilation and systemic congestion, contributes to exacerbating the risk of thromboembolic events. Although the study was not specifically designed to compare antithrombotic treatment regimens in patients with uRV, 10 , 27 it highlights the importance of future research to determine optimal preventive therapeutic strategies. Limitations The TACTIC study is observational and retrospective. It is subject to constraints associated with unmeasured or unknown confounders, a limited ability to control for several potential confounders (due in part to small numbers of events), and data not available from medical and surgical charts. Management decisions and follow‐up protocols were not standardized and were, therefore, at the discretion of the treating teams. In an effort to maximize data accuracy and completeness, the study was designed with strict data processing and quality control standards, including an independent adjudication committee. Surgical era was considered among the candidate variables for the multivariable model but did not reach the threshold for retention. Considering that earlier Fontan surgeries were predominantly performed for patients with non‐HLHS (Figure 1), the direction of any bias resulting from the noninclusion of surgical era in the multivariable model is toward the null hypothesis, thereby yielding conservative estimates of risks associated with HLHS versus non‐HLHS. Finally, generalizing the results should be approached with caution, as the study was confined to patients who survived all stages of Fontan palliation and were followed in the same tertiary center that performed the surgery. CONCLUSIONS In conclusion, this North American multicenter study revealed that, among patients with uRV and total cavopulmonary connection Fontan palliation, HLHS is associated with a significantly amplified risk of adverse cardiovascular events, namely atrial arrhythmia, thromboembolic event, cardiac transplantation, or death. The findings underline the important need for targeted interventions and focused research to address the complex challenges associated with this growing and aging high‐risk patient cohort. Sources of Funding The TACTIC study was funded by an investigator‐initiated unrestricted grant from Boehringer Ingelheim. The sponsor had no role in the study design, data collection, analysis, interpretation, writing of the paper, and decision to submit the article for publication. P.K. is supported by the André Chagnon research chair in electrophysiology and congenital heart disease. N.D. is supported by the French Federation of Cardiology and ADETEC grants. Disclosures None.